Exco InTouch Secures The Journal Of mHealth’s 2016 Global Digital Health 100 Award For A Third Year In A Row
11/29/2016 9:47:15 AM
Accolade recognizes the company as one of the leading innovators in the mobile and digital health industry
28 November 2016: Exco InTouch, the leading provider of intelligent digital health programs for healthcare and biopharmaceutical companies, has been recognized for the third year running as an honoree in the Journal of mHealth’s Global Digital Health 100. The 2016 list – compiled from a combination of nominations and industry research by the publication’s international team - sets out to identify the most innovative and disruptive health technology companies from across the globe that operate in the mobile, digital and connected care industries.
The company, which provides digital services and solutions that support long-term condition management to drive better health outcomes, is firmly established as a market leader and industry authority in digital health. Exco InTouch’s modular approach delivers disease management programs that support all stakeholders in the care circle including patients, caregivers, healthcare professionals and providers. This enables the development of tailored, condition-specific care plans for which the most appropriate tools for each individual program are selected - ranging from data capture, education, alerts, goals, progress tracking and patient monitoring through role-based access and reporting. Through this approach, patients are able to learn more about their condition, remain engaged with treatment regimens and ultimately better manage their conditions. Exco InTouch’s digital health platform has already been implemented in key therapeutic areas such as diabetes, dermatology, respiratory diseases and hemophilia.
One such program is TARGET My Hives, a digital support network bringing together patients, clinicians and patient advocacy groups impacted by chronic urticaria. This online community provides support, increases awareness and reduces the sense of isolation that many sufferers feel. The program enables patients to learn how to manage their disease, set goals for themselves and share experiences and results. Moreover, the Me&MyCOPD program, developed in collaboration with AstraZeneca, enables patients suffering from chronic obstructive pulmonary disease, caregivers and healthcare providers to collect, transmit, track and review clinical data.
Tim Davis, CEO and founder of Exco InTouch, commented: “We are very pleased to be recognized as an honoree on the Digital Health 100 List for the third year running. Securing this award reflects our sustained track record of achievement in this field as well as our continued commitment to improving the healthcare experience for patients everywhere.”
For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 207 203 6740 or e-mail: email@example.com.
About Exco InTouch
Exco InTouch is the leading provider of intelligent digital health programs for healthcare and biopharmaceutical companies. Placing the patient at its heart, their proven technology can be employed on any device to create patient engagement and data capture solutions that empower patients to be more involved in their healthcare and ultimately lead to better health outcomes. These solutions capitalize upon global mobile device and internet usage, using mDNA® technology to facilitate secure deployment to patients’ own mobile devices, enabling seamless integration of disease management programs into their daily life. This results in motivated and compliant patients across a wealth of therapeutic, demographic and geographic programs in clinical and commercial settings.
Since 2004, Exco InTouch have engaged with over one million patients across 97 countries, over 32,000 hospitals and clinics and in 70 languages. 16 of the top 20 pharmaceutical companies have deployed their technology.
About Global Digital Health 100
In recognition of the ever-growing significance of the mobile and digital technology sectors, the Digital Health 100 award represents six months of assessment and analysis of large, small and medium sized companies from across the digital health ecosystem. The Journal of mHealth’s editorial and advisory team applied 10 different quantitative and qualitative evaluation criteria, ranging from technological innovation, disruptive impact, proof of concept and social value, right through to effectiveness, execution of strategy and industry integration.
comments powered by